Clinical trial
Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or…
NCT00002681 · Roger Williams Medical Center, Other · Completed
Key facts
| NCT number | NCT00002681 |
|---|---|
| Title | Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma |
| Official title | Humanized Anti-Tac Antibody Therapy In Hodgkin's Disease, A Phase Ib/II Trial |
| Lead sponsor | Roger Williams Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Beth Israel Deaconess Medical Center |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Biological |
| Interventions | aldesleukin, daclizumab |
| Enrollment | 25 |
| Start date | Jul 1, 1995 |
| Primary completion | Sep 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 10, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: